Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the bodyâs natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunonâs DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 25 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
26-01-13	3.800 $	+6.74%	80,778
26-01-12	3.560 $	-3.52%	45,849
26-01-09	3.690 $	-4.40%	43,877
26-01-08	3.860 $	-1.53%	36,142
26-01-07	3.920 $	-0.76%	37,212

Delayed Quote Nasdaq, January 13, 2026 at 04:00 pm EST

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.800USD

Average target price

24.33USD

Spread / Average Target

+540.35%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-13 pm EST			5-day change	1st Jan Change
3.800 ^USD	+6.74%		-3.80%	-0.26%

Jan. 07	Imunon Inc - Interim CFO Kimberly Graper to resign January 14, 2026 - SEC filing	RE
Jan. 07	Imunon, Inc. Announces Executive Changes, Effective January 14, 2026	CI

Capitalization	12.92M 11.1M 10.35M 9.62M 17.95M 1.17B 19.36M 119M 46.77M 558M 48.46M 47.46M 2.06B	P/E ratio 2025 *	-0.2x	P/E ratio 2026 *	-1.05x
Enterprise value	12.92M 11.1M 10.35M 9.62M 17.95M 1.17B 19.36M 119M 46.77M 558M 48.46M 47.46M 2.06B	EV / Sales 2025 *	-	EV / Sales 2026 *	-
Free-Float	98.91%	Yield 2025 *	-	Yield 2026 *	-

Jan. 07	Imunon Inc - Interim CFO Kimberly Graper to resign January 14, 2026 - SEC filing	RE
Jan. 07	Imunon, Inc. Announces Executive Changes, Effective January 14, 2026	CI
Jan. 07	Imunon, Inc. Announces Chief Financial Officer Changes, Effective January 14, 2026	CI
Dec. 30	Imunon to Raise Roughly $7 Million From Registered Direct Offering	MT
Nov. 13	Imunon, Inc., Q3 2025 Earnings Call, Nov 13, 2025
Nov. 13	Imunon, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 10	Imunon, Inc. - Special Call
Nov. 10	IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer	CI
Nov. 10	IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer	CI
Nov. 07	Imunon research and development day: opportunity to hear clinical trial investigators discuss significant potential of IMNN-001 to redefine ovarian cancer treatment	RE
25-10-23	IMUNON, Inc. to Present New Translational Data from Phase 2 Ovarian Cancer at SITC 40th Annual Meeting	CI
25-10-14	IMUNON, Inc. to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress	CI
25-09-22	IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month Os Extension Via Tumor Micro- Environment Shift	CI

25-10-23	IMUNON, Inc. to Present New Translational Data from Phase 2 Ovarian Cancer at SITC 40th Annual Meeting	CI
25-05-23	Sector Update: Health Care Stocks Softer Friday Afternoon	MT
24-07-31	Top Midday Decliners	MT
24-04-01	HC Wainwright Adjust Price Target on Imunon to $13 From $12, Keeps Buy Rating	MT
22-10-13	Alliance Global Starts Imunon at Buy with $15 Price Target	MT

Imunon, Inc. Stock

Equities

IMNN

US15117N7012

Biotechnology & Medical Research

Valuation: Imunon, Inc.

Chart: Imunon, Inc.

Latest news: Imunon, Inc.

Last Transcript: Imunon, Inc.

Analysts' recommendations: Imunon, Inc.

Press Releases: Imunon, Inc.

News in other languages: Imunon, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Imunon, Inc.

ETFs: Imunon, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Dec. 30	IMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules	AQ
Dec. 29	IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026	AQ
Nov. 13	IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
Nov. 10	IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer	AQ
Nov. 10	IMUNON : R&D Day Highlighting Progress on OVATION 3 Study	PU

23-01-12	Euroapi: Mattias Perjos, PDG de Getinge, nouvel administrateur indépendant
23-01-12	Euroapi : cooptation d'un nouvel administrateur
21-01-21	Alcoa : MÄRKTE USA/Nach neuen Hochs geht Wall Street die Luft aus

1 day	+6.74%
1 week	-3.80%
Current month	-0.26%
1 month	-8.43%
3 months	-24.30%
6 months	-51.85%
Current year	-0.26%

1 week	3.51	3.99
1 month	2.99	4.2
Current year	3.51	4.2
1 year	2.99	41.22
3 years	2.99	47.61
5 years	2.99	680.87
10 years	2.99	4,875.69

Manager	Title	Age	Since
Stacy Lindborg CEO	Chief Executive Officer	56	2024-05-12
Douglas Faller CTO	Chief Tech/Sci/R&D Officer	73	2025-02-17
Khursheed Anwer CTO	Chief Tech/Sci/R&D Officer	66	2014-06-19

Director	Title	Age	Since
Michael Tardugno CHM	Chairman	75	2014-10-06
Frederick Fritz BRD	Director/Board Member	75	2011-07-07
Donald Braun BRD	Director/Board Member	76	2015-12-14

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
IMUNON, INC.	+6.74%	-3.80%	-68.20%	-81.79%	12.11M
ARGENX SE	+3.75%	+1.96%	+8.23%	+89.61%	48.01B
WUXI APPTEC CO., LTD.	+6.00%	+8.68%	+96.73%	+14.95%	41.97B
INSMED INCORPORATED	-2.38%	-6.48%	+137.52%	+741.75%	35.77B
BIONTECH SE	+4.90%	+9.28%	-5.76%	-26.10%	25.64B
GENMAB A/S	-0.74%	+6.77%	+33.50%	-21.62%	20.81B
WUXI BIOLOGICS (CAYMAN) INC.	+5.85%	+18.68%	+131.28%	-41.71%	19.92B
SUMMIT THERAPEUTICS INC.	-1.35%	-9.91%	-7.51%	+250.21%	13.14B
AKESO, INC.	-4.36%	+2.99%	+114.78%	+162.46%	14.9B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.68%	+11.30%	+190.69%	-	14.63B
Average	+2.03%	+3.46%	+63.13%	+120.86%	23.48B
Weighted average by Cap.	+2.18%	+3.67%	+72.14%	+159.95%

	2025 *	2026 *
Net sales	-	-
Net income	-21.99M -18.9M -17.62M -16.37M -30.55M -1.99B -32.94M -203M -79.6M -949M -82.47M -80.78M -3.5B	-25.47M -21.89M -20.41M -18.97M -35.39M -2.3B -38.16M -235M -92.2M -1.1B -95.53M -93.57M -4.05B
Net Debt	-	-